Literature DB >> 3654149

The colony inhibition of a new chemotherapeutic agent (KW2152) against human lung cancer cell lines.

J R Jett1, N Saijo, W S Hong, Y Sasaki, H Takahashi, H Nakano, K Nakagawa, M Sakurai, K Suemasu, M Tesada.   

Abstract

The human tumor colony assay was used to evaluate the effect of a new chemotherapeutic agent (KW2152) on colony inhibition of four non-small cell lung cancer cell lines and a mouse cell line. With continuous exposure experiments, KW2152 induced greater than or equal to 70% colony inhibition of PC-7 (human adenocarcinoma), PC-10 (human squamous cell) and PC-13 (human large cell) at a drug concentration of 10 mcg/ml. In one hour exposure experiments, KW2152 caused a significant reduction in colony formation (less than or equal to 30% of control) only at the highest concentration tested (100 mcg/ml). KW2152 showed significant in vitro activity against human non-small cell lung cancer cell lines. Due to these promising results, it was suggested that KW2152 should be evaluated in clinical trials.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3654149     DOI: 10.1007/BF00203540

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  15 in total

1.  Cancer statistics. 1986.

Authors:  E Silverberg
Journal:  CA Cancer J Clin       Date:  1986 Jan-Feb       Impact factor: 508.702

2.  Primary bioassay of human myeloma stem cells.

Authors:  A Hamburger; S E Salmon
Journal:  J Clin Invest       Date:  1977-10       Impact factor: 14.808

Review 3.  Chemotherapy of metastatic non-small cell bronchogenic carcinoma.

Authors:  P C Hoffman; J D Bitran; H M Golomb
Journal:  Semin Oncol       Date:  1983-03       Impact factor: 4.929

4.  Human tumor colony assay and chemosensitivity testing.

Authors:  S E Salmon
Journal:  Cancer Treat Rep       Date:  1984-01

5.  A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer.

Authors:  J C Ruckdeschel; D M Finkelstein; D S Ettinger; R H Creech; B A Mason; R A Joss; S Vogl
Journal:  J Clin Oncol       Date:  1986-01       Impact factor: 44.544

6.  The use of human cancer cell lines as a primary screening system for antineoplastic compounds.

Authors:  G J Finlay; B C Baguley
Journal:  Eur J Cancer Clin Oncol       Date:  1984-07

7.  Clonogenic patterns of human pulmonary adenocarcinoma cell lines (PC-9, PC-13 and PC-14) and how they influence the results of test for chemosensitivity to cisplatin in the human tumor clonogenic assay.

Authors:  Y C Lee; N Saijo; Y Sasaki; H Takahashi; M Sakurai; J Ishihara; A Hoshi; K M Chen; A W Hamburger
Journal:  Jpn J Clin Oncol       Date:  1985-12       Impact factor: 3.019

8.  Application of a human tumor colony-forming assay to new drug screening.

Authors:  R H Shoemaker; M K Wolpert-DeFilippes; D H Kern; M M Lieber; R W Makuch; N R Melnick; W T Miller; S E Salmon; R M Simon; J M Venditti
Journal:  Cancer Res       Date:  1985-05       Impact factor: 12.701

9.  Human tumor cloning: feasibility and clinical correlations.

Authors:  D D Von Hoff; J Cowan; G Harris; G Reisdorf
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

10.  Prospective clinical trial of a human tumor cloning system.

Authors:  D D Von Hoff; G M Clark; B J Stogdill; M F Sarosdy; M T O'Brien; J T Casper; D E Mattox; C P Page; A B Cruz; J F Sandbach
Journal:  Cancer Res       Date:  1983-04       Impact factor: 12.701

View more
  1 in total

1.  Disposition of DX-52-1, a novel anticancer agent, after intravenous administration to mice and dogs.

Authors:  E Fuse; H Nishiie; H Kobayashi; S Ikeda; H Saito; J Covey; S Kobayashi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1997 Jan-Mar       Impact factor: 2.441

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.